Inventor
ROMANO CARMELO
US16 patents
⚠️ This page may combine multiple inventors who share the name “ROMANO CARMELO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
13 patentsUS10633434B2Apr 28, 2020
Anti-C5 antibodies
REGENERON PHARMA20 citations93
US11492392B2Nov 8, 2022
Polynucleotides encoding anti-C5 antibodies
REGENERON PHARMA1 citations72
US11479602B2Oct 25, 2022
Methods of treating C5-associated diseases comprising administering anti-C5 antibodies
REGENERON PHARMA1 citations72
US12396444B2Aug 26, 2025
Mouse comprising a humanized TRKB locus
REGENERON PHARMA0 citations62
US11419318B2Aug 23, 2022
Genetically modified rat comprising a humanized TRKB locus
REGENERON PHARMA1 citations62
US12082565B2Sep 10, 2024
Non-human animals models of retinoschisis
REGENERON PHARMA0 citations60
US11865134B2Jan 9, 2024
Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors
REGENERON PHARMA0 citations60
US11767526B2Sep 26, 2023
Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
REGENERON PHARMA0 citations57
US11845989B2Dec 19, 2023
Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
REGENERON PHARMA0 citations56
US12370257B2Jul 29, 2025
Materials and methods of treating MHC-I-opathy risk haplotypes
REGENERON PHARMA0 citations52
US12521451B2Jan 13, 2026
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
REGENERON PHARMA0 citations51
US12582104B2Mar 24, 2026
Mutant myocilin disease model and uses thereof
REGENERON PHARMA0 citations50
US12157891B2Dec 3, 2024
Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
REGENERON PHARMA0 citations38